

Regd. Office: Barodawala Mansion,

B-Wing, 3rd Floor,

81, Dr. Annie Besant Road, Worli, Mumbai - 400 018.

l. ; +

: +91 22 6987 9900 : 3511 3710/23/25/28

LLPIN

: AAT - 7548

Website : www.mmnissim.com

INDEPENDENT AUDITOR'S REPORT

Report on the Audit of the Standalone Ind AS Financial Statements

To the Members of Advanced Bio Agro Tech Limited

Opinion

We have audited the separate financial statements (also known as Standalone Financial Statements) of Advanced Bio Agro Tech Limited, (hereinafter referred to as "Company") which comprise the Balance Sheet as at 31st March, 2025, and the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of the state of affairs (financial position) of the Company as at 31st March 2025, and its profit(financial performance including Other Comprehensive Income), the Changes in Equity and its Cash Flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial Statements.

Other Information

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report including annexure to Board's report, Management Discussion and Analysis, but does not include the financial statements and our auditor's report thereon

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Standalone Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.





If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard

Responsibilities of Management for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, Changes in Equity and Cash Flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibility for the Audit of the standalone financial statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion, The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to
 design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i)
 of the Act, we are also responsible for expressing our opinion on whether the Company has
 adequate internal financial controls with reference to financial statements in place and the
 operating effectiveness of such controls.





- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards prescribed under section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025t from being appointed as a director in terms of Section 164 (2) of the Act.





- f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) As required by section 197(16) of the Act, based on our audit, we report that the Company has paid and provided for remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us
 - The company has no pending litigations which could have impact on its financial position in the financial statements except as stated in Note 38 to the Standalone Financial Statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses
 - iii. There were no amounts required to be transferred, to the Investor Education Protection Fund by the Company.
 - iv. (a) As represented to us by the management and to the best of its knowledge and belief, no funds have been advanced or lend or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities (Intermediaries"), with the understanding whether recorded in writing or otherwise that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (b) As represented to us by the management and to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.





- v. The Company has complied with the provisions with respect to Section 123 of the Companies Act, 2013 in respect of declaration and/or payment of dividend during the year.
- vi. Based on our examination which included test checks, the company has maintained an audit trail (edit log) facility as prescribed under Rule 3(1) of the Companies (Accounts) Rules, 2014 as amended, in respect of all the transactions recorded in the accounting software for the financial year ended March 31, 2025, and the same has been operated throughout the year for all relevant transactions. Further, the audit trail feature has not been tampered with and has been preserved by the company as per the statutory requirements.

For M M Nissim & Co LLP

Chartered Accountants (Firm Regn. No. 107122W/W100672)

FRN: 107122W / W100672

MUMBAI

Dimple Maru Partner

Mem. No.: 141312

Mumbai, 26" April, 2025 UDIN:- 25141312BMJKDJ2599



ANNEXURE - A TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE IND-AS FINANCIAL STATEMENTS OF ADVANCED BIO-AGRO TECH LIMITED

Report on the Order issued under Section 143 (11) of the Companies Act, 2013

 i) a) A) The company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment;

B) The company does not have intangible assets and hence provisions of clause (iaB) of

Para 3 of the Order are not applicable to the Company

- b) The Property, Plant & equipment have been physically verified by the management in accordance with a regular programme of verification, which in our opinion is reasonable, considering the size and the nature of its business. The frequency of verification is reasonable and no material discrepancies have been noticed on such physical verification;
- c) Based on our examination of the registered sale deed / transfer deed / conveyance deed / provided to us, we report that, the title deeds of all the immovable properties disclosed in the financial statements included in property, plant and equipment are held in the name of the Company as at the balance sheet date.
- d) The company has not revalued its Property, Plant & Equipment during the year.
- e) No proceedings have been initiated during the year or are pending against the Company as at 31st March 2025 for holding any benami property under the Benami Transaction (Prohibition) Act, 1988, as amended and rules made thereunder.
- ii) a) The inventory has been physically verified by the management during the year at reasonable intervals. In our opinion, the coverage and procedure of such verification by the management is appropriate having regard to the size of the Company and the nature of its operation. No discrepancies of 10% or more in the aggregate for each class of inventory were noticed on such physical verification of inventory when compared with books of account.
 - b) The Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.
- iii) The Company has not made any investments in, provided any guarantee or security, and granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties during the year, and hence reporting under clause (iii) of the Order is not applicable to the Company.
- iv) In our opinion, in respect of investments made, the Company has complied with the provisions of Section 186 of the Act.
- v) The Company has not accepted any deposits or amounts which are deemed to be deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 as amended. Accordingly, the provisions of clause 3(v) of Para 3 of the Order are not applicable to the Company.





- vi) The maintenance of cost records has not been specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 for the business activities carried out by the Company. Hence, reporting under clause (vi) of the Order is not applicable to the Company.
- vii) (a) In our opinion, the company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Sales-Tax, Service Tax, Goods & Services Tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues with appropriate authorities, where applicable. According to the information and explanations given to us, there are no undisputed amounts payable in respect of such statutory dues which remained outstanding as at 31st March 2025 for a period of more than six months from the date they became payable except TDS defaults amounting to Rs. 0.02 Million.

(b) According to the records of the Company, there are no dues outstanding in respect of income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, goods and service tax, and cess on account of any dispute except as follows;

| Statute and nature of dues | Financial year to which the matter pertains | Forum where dispute is pending | Amount in Million |
|----------------------------|---|--------------------------------|----------------------|
| Income Tax Act, 1961 | 2020-21 | CIT - Appeals | 3.24 |

- viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
- ix) a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
 - b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
 - c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
 - d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the Company, funds raised on short-term basis have, *prima facie*, not been used during the year for long-term purposes by the Company.
 - e) The Company did not have any subsidiary or associate or joint venture during the year and hence, reporting under clause (ix)(e) of the Order is not applicable.
 - f) The Company has not raised any loans during the year and hence reporting on clause (ix)(f) of the Order is not applicable.
- x) a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause 3(x)(a) of the Order is not applicable.





- b) The Company has not made any preferential allotment or private placement of share or fully convertible debentures (fully, partially or optionally convertible) during the year and accordingly provisions of clause (x)(b) of Para 3 of the Order are not applicable to the Company.
- xi) a) On the basis of our examination and according to the information and explanations given to us, no fraud by the Company or any material fraud on the Company has been noticed or reported during the year, nor have we been informed of any such case by the management.
 - b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year.
 - c) As represented to us by the management, there are no whistle blower complaints received by the company during the year
- xii) The company is not a nidhi Company and accordingly provisions of clause (xii) of Para 3 of the order are not applicable to the Company.
- xiii) On the basis of our examination and according to the information and explanations given to us, we report that all the transaction with the related parties are in compliance with Section 177 and 188 of the Act, to the extend applicable, and the details have been disclosed in the Standalone Financial statements in Refer Note 35 as required by the applicable accounting standards.
- xiv) In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act 2013. Accordingly, provisions of clause (xiv)(b) of Para 3 of the Order are not applicable to the company.
- xv) Based on our examination of the records of the company, the company has not entered into any non-cash transactions with directors or persons connected with the directors. Accordingly, provisions of clause (xv) of Para 3 of the Order are not applicable to the company.
- xvi) (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and accordingly, provisions of clause (xvi) of Para 3 of the Order are not applicable to the Company.
 - (b) During the year, the Company has not conducted any Non-Banking Financial or Housing Finance activities and accordingly, provisions of clause (xvi)(b) of Para 3 of the Order are not applicable to the Company.
 - (c) The Company is not a Core Investment Company (CIC) as defined in the Regulations made by the Reserve Bank of India and accordingly the provisions of clause (xvi) of Para 3 of the Order is not applicable to the Company.
 - (d) The group does not have any CIC as a part of the group and accordingly reporting under clause (xvi)(d) of Para 3 of the Order is not applicable to the Company.





- xvii) The Company has not incurred cash losses during the Financial Year covered by our audit and in the immediately preceding Financial Year.
- xviii) There has been no resignation of the statutory auditors of the Company during the year.
- On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act.
- xxi) The Company has no subsidiaries, associates and joint ventures and accordingly reporting under Para 3(xxi) is not applicable to the Company.

& MIS

107122W / W1006**72** MUMBAI

For M M Nissim & Co LLP

Chartered Accountants (Firm Regn. No. 107122W/W100672)

Dimple Maru
Partner

Mem. No.: 141312

Mumbai, 26th April, 2025 UDIN:- 25141312BMJKDJ2599



ANNEXURE - B

TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS OF ADVANCED BIO-AGRO TECH LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to Financial Statements of Advanced Bio-Agro Tech Limited as of March 31, 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to Financial Statements and such controls were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the Institute of Chartered Accountants of India(ICAI).

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") issued by Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of Internal Financial Controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Financial Statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Financial Statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to Financial Statements.





Meaning of Internal Financial Controls with reference to Financial Statements

A Company's internal financial control with reference to Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements

Inherent Limitations of Internal Financial Controls with reference to Financial Statements Because of the inherent limitations of internal financial controls with reference to Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Financial Statements to future periods are subject to the risk that the internal financial control with reference to Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

> SIM & C FRN: 107122W /

W100672

MUMBAI

For M M Nissim & Co LLP

Chartered Accountants (Firm Regn. No. 107122W/W100672)

Dimple Maru Partner

Mem. No.: 141312 Mumbai, 26th April, 2025

UDIN:- 25141312BMJKDJ2599

Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Balance Sheet as at 31 March 2025

| (Rs in millions) | Note | As at 31 March 2025 | As at 31 March 2024 |
|--|------|------------------------|------------------------|
| I. ASSETS | | | |
| (1) Non-current assets | | | |
| (a) Property, Plant and Equipment | 3 | 18.99 | 19.44 |
| (b) Deferred tax assets (net) | 4 | 2.24 | 1.61 |
| (c) Income tax asset | | 10.23 | 9.64 |
| (d) Other non-current assets | 5 | 0.30 | 0.30 |
| Total non-current assets | _ | 31.76 | 30.99 |
| (2) Current Assets | | | |
| (a) Inventories | 6 | 6.76 | 3.95 |
| (b) Financial Assets | | | |
| (i) Investments | 7 | 42.48 | 59.60 |
| (ii) Trade receivables | 8 | 120.02 | 121.95 |
| (iii) Cash and cash equivalents | 9 | 17.49 | 14.80 |
| (iv) Bank balances other than (iii) above | 9 | 45.00 | 45.00 |
| (v) Loans | 10 | 0.77 | 0.59 |
| (vi) Others | 11 | 1.70 | 1.74 |
| (d) Other current assets | 12 | 5.28 | 6.94 |
| (d) one curent assets | | 239.50 | 254.57 |
| Total assets | _ | 271.26 | 285,56 |
| Total about | | 271.20 | 200,00 |
| II. EQUITY AND LIABILITIES | | | |
| (1) Equity | | | |
| (a) Equity share capital | 13 | 1.00 | 1.00 |
| (b) Other equity | 14 _ | 230.89 | 234.58 |
| | _ | 231.89 | 235,58 |
| Total equity | _ | 231.89 | 235.58 |
| (2) Non current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 15 | 1.53 | 2.97 |
| Total non current liabilities | | 1.53 | 2,97 |
| (2) Current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 15 | 1.44 | 1.34 |
| (ii) Trade payables | 16 | | |
| - Outstanding dues of micro enterprises and small enterprises | | | |
| - Outstanding dues of creditors other than micro enterprises and small | | 10.30 | 19.60 |
| enterprises | 224 | 0.00 | 7.70 |
| (iii) Other financial Liabilities | 17 | 9.92 | 7.49 |
| (b) Other current liabilities | 18 | 15.07 | 17.19 |
| (c) Current provisions | 19 _ | 1.11 | 1.39 |
| Total Current liabilities | - | 37.84 | 47.01 |
| Total liabilities | - | 271.26 | 285.56 |

The accompanying notes form an integral part of the financial statements.

As per our report of even date attached

For M M Nissim & Co LLP

122W/W100672

Dimple Maru Partner

M. No.: 141312

Place : Mumbai Date: 26th April, 2025

UDIN - 25141312BMJKDJ2599

For and on behalf of Board of Directors of Advanced Bio-Agro Tech Limited

CIN No: U24100MH2004PLC149464

Managing Director

DIN: 00015162 Place: Pune

Date: 26/04/2025

Mukund M. Kabra Director DIN: 00148294 Place: Nashik

Date: 26/04/2025

Beni P. Rauka Director DIN: 00295213

Place: Thane Date: 26/04/2025

Statement of Profit and Loss for the year ended 31 March 2025

(Rs in millions)

| | , | Note | 31 March 2025 | 31 March 2024 |
|-------|---|------|---------------|---------------|
| | Income: | | | |
| I. | Revenue from contracts with customers | 20 | 478.82 | 448.27 |
| II. | Other Income | 21 | 7.82 | 7.30 |
| III. | Total Income (I + II) | | 486.64 | 455.57 |
| | Expenses: | | | |
| | Purchases of Stock-in-Trade | 22 | 305.44 | 280.95 |
| | Changes in inventories of Stock-in-Trade | 23 | (2.81) | 1.71 |
| | Employee benefits expense | 24 | 55.84 | 51.38 |
| | Finance costs | 25 | 0.47 | 0.50 |
| | Depreciation and amortization expense | 3 | 2.08 | 2.81 |
| | Other expenses | 26 | 74.71 | 63.31 |
| IV. | Total expenses | | 435.73 | 400.66 |
| V. | Profit before tax (III- IV) | | 50.91 | 54.91 |
| VI. | Tax expenses: | 31 | | |
| | 1. Current tax | | 13.34 | 13.22 |
| | (Excess) / short provision for earlier years | | 1.95 | 0.54 |
| | Net current tax | | 15.29 | 13.77 |
| | 2. Deferred tax | | (0.65) | 0.91 |
| VII. | Profit for the year (V - VI) | | 36.27 | 40.24 |
| VIII. | Other comprehensive income | | | |
| | A (i) Items that will not be reclassified to profit or loss - Remeasurement of Defined Benefit Plans | | (0.08) | (0.26) |
| | (ii) Income tax related to items that will not be reclassified | | 0.02 | 0.07 |
| | to profit or loss | 31 | | |
| | Other comprehensive income / (loss) for the year, net of tax | | (0.06) | (0.20) |
| IX. | Total comprehensive income for the year | | 36.33 | 40.43 |
| X. | Earnings per equity share | . 29 | | |
| | Basic earnings per share | | 362.65 | 402.38 |
| | Diluted earnings per share | | 362.65 | 402.38 |

The accompanying notes form an integral part of the financial statements.

As per our report of even date attached

For M M Nissim & Co LLP

Chartered Accountants

Firm Registration no. 107122W/W100672

Dimple Maru Partner

M. No.: 141312 Place: Mumbai

Date: 26th April, 2025

UDIN - 25141312BMJKDJ2599

For and on behalf of Board of Directors of Advanced Bio-Agro **Tech Limited**

CIN No: U24100MH2004PLC149464

Managing Director DIN: 00015162

Place: Pune Date: 26/04/2025 Mukund M. Kabra Director DIN: 00148294

Place: Nashik Date: 26/04/2025 Beni P. Rauka Director DIN: 00295213 Place: Thane

Date: 26/04/2025

| | 31 March 2025 | 31 March 2024 |
|--|---------------|---------------|
| Opening Balance | 4.32 | 5,57 |
| Inflow from Long Term Borrowings | | |
| Outflow from Long Term Borrowings | (1.35) | (1.25) |
| Cash inflow /(outflow) of current borrowings | | - |
| Closing Balance | 2.97 | 4.32 |

CIN No: U24100MFI2004PLC149464

As per our attached Report of even date

For M M Nissim & Co LLP

Chartered Accountants

Firm Registration no. 107122

NISSIM Dimple Maru Partner MUMBAI M. No.: 141312 Place: Mumbai Date: 26th April, 2025

UDIN - 25141312BMJKDJ2599

lanaging Director OIN: 00015162 Place: Pune Date: 26/04/2025

100672

(y. w.) (a) Mukund M! Kabra Director DIN: 00148294

For and on behalf of Board of Directors of Advanced Bio-Agro Tech Limited

Place: Nashik Date: 26/04/2025

P. Rauka DIN: 00295213 Place: Thane Date: 26/04/2025

Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Statement of Changes in Equity (SOCIE)

for the year ended 31 March 2025

(a) Equity share capital (refer note 13)

Balance at the beginning of the year Changes in equity share capital due to prior period errors Restated balance at the beginning of the current reporting year Changes in equity share capital during the year Balance at the end of the year

| As at 31 March 2025 | | As at 31 March 2024 | | | |
|---------------------|-----------|---------------------|-----------|--|--|
| No. of Shares | Amount | No. of Shares | Amount | | |
| 1,00,000 | 10,00,000 | 1,00,000 | 10,00,000 | | |
| (94) | - | | - | | |
| 1,00,000 | 10,00,000 | 1,00,000 | 10,00,000 | | |
| 14 | 141 | 2 | | | |
| 1,00,000 | 10,00,000 | 1,00,000 | 10,00,000 | | |

(i) Out of the total 1,00,000 shares, 60,000 shares are held by Advanced Enzyme Technologies Ltd, the holding company

(ii) Particulars of shareholders holding more than 5%

| Name of Shareholder | No. of Shares held | % of Holding | No. of Shares held | % of Holding |
|--|--------------------|--------------|--------------------|--------------|
| M/s. Advanced Enzyme Technologies Ltd and its nominees | 60,000 | 60% | 60,000 | 60% |
| Mr. Omprakash B. Singh | 40,000 | 40% | 40,000 | 40% |

(b) Other equity (refer note 14)

Rs in millions

| (b) Other equity (refer note 14) | | | | Rs in millions |
|--|-----------------|-------------------|---|----------------|
| | Reserves 8 | ¿ Surplus | OCI- | Total Equity |
| Particulars | General reserve | Retained earnings | Remeasurement of defined benefit obligation | |
| Balance as at 31 March 2023 | 6.23 | 207.92 | | 214.16 |
| Profit for the year | | 40.23 | 70 | 40.23 |
| Other comprehensive income for the year | | | 0.20 | 0.20 |
| Total comprehensive income for the year | | 40.23 | 0.20 | 40.42 |
| Interim Dividends per share at Rs. 200 per share | | (20.00) | | (20.00) |
| Balance as at 31 March 2024 | 6.23 | 228.15 | 0.20 | 234.58 |
| Profit for the year | _ | 36.26 | | 36.26 |
| Other comprehensive income for the year | | 1 2 | 0.06 | 0.06 |
| Total comprehensive income for the year | | 36.26 | 0.06 | 36.31 |
| Interim dividend at Rs. 400 per share | 1172 | (40.00) | | (40.00) |
| Balance as at 31 March 2025 | 6.23 | 224.41 | 0.25 | 230.89 |

Nature and component of equity:

General Reserve

General Reserve represents accumulated profits and is created by transfer of profits from Retained Earnings and it is not an item of Other Comprehensive Income and the same shall not be subsequently reclassified to Statement of Profit and Loss

Retained Earnings

Retained Earnings are Profits that the company has earned till date less any transfers to General Reserves and Dividends.

Remeasurements of Defined Benefit Plans

Gains / Losses arising on Remeasurements of Defined Benefit Plans are recognised in the Other Comprehensive Income as per IND AS-19 and shall not be reclassified to the Statement of Profit or Loss in the subsequent years.

The accompanying notes form an integral part of the financial statements.

As per our report of even date attached

For M M Nissim & Co LLP

Chartered Accountants

Firm Registration no. 107122W/W100672

For and on behalf of Board of Directors of Advanced Bio-Agro Tech Limited

CIN No: U24100MH2004PLC149464

Dimple Maru Partner

M. No.: 141312 Place : Mumbai Date: 26th April, 2025

UDIN - 25141312BMJKDJ2599

O. P. Singh Managing Directo

Managing Director DIN: 00015162 Place: Pune Date: 26/04/2025 Mukund M. Kabra Director DIN: 00148294 Place: Nashik

Date: 26/04/2025

Bent P, Rauka Director DIN: 00295213 Place: Thane Date: 26/04/2025

Notes to the Standalone Financial Statements for the year ended 31 March 2025

1 Overview of the Company

Advanced Bio-Agro Tech Limited ("the Company") was incorporated on 9 November 2004 and is primarily engaged in business of trading of poultry feed and agri products.

2 Basis of preparation of financial statements

Statement of compliance

The Financial statements of the Company comply with all material aspects with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the Act) [Companies (Indian Accounting Standards) Rules, 2015] and other relevant provisions of the Act.

The financial statements of the Company for the year ended 31 March 2025 were authorised for issue in accordance with a resolution of the directors on 26th April 2025

Functional and presentation currency

These financial statements are presented in Indian rupees, which is also the Company's functional currency.

Basis of measurement

The financial statements have been prepared on a historical cost basis, except for the following:

- · certain financial assets and liabilities (including derivative instruments) that are measured at fair value; and
- · net defined benefit (asset)/ liability that are measured at fair value of plan assets less present value of defined benefit obligations.

2A Use of estimates

The preparation of the financial statements in accordance with Ind AS requires use of judgements, estimates and assumptions, that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised prospectively.

Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment in the year ended 31 March 2025 are as follows:

a. Property, plant and equipment

Determination of the estimated useful lives of tangible assets and the assessment as to which components of the cost may be capitalised. Useful lives of tangible assets are based on the life prescribed in Schedule II of the Act. In cases, where the useful lives are different from that prescribed in Schedule II, they are based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers' warranties and maintenance support.

b. Recognition and measurement of defined benefit obligations

The obligation arising from defined benefit plan is determined on the basis of actuarial assumptions. Key actuarial assumptions include discount rate, trends in salary escalation, actuarial rates and life expectancy. The discount rate is determined by reference to market yields at the end of the reporting period on government bonds. The period to maturity of the underlying bonds correspond to the probable maturity of the post-employment benefit obligations.

c. Recognition of deferred tax assets

Deferred tax assets are recognised for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases, and unutilised business loss and depreciation carry-forwards and tax credits. Deferred tax assets are recognised to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses, depreciation carry-forwards and unused tax credits could be utilised.

d Measurement of fair values

The Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

The Company has an established control framework with respect to the measurement of fair values, which includes overseeing all significant fair value measurements, including Level 3 fair values by the management. The management regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as broker quotes or pricing services, is used to measure fair values, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of Ind AS, including the level in the fair value hierarchy in which such valuations should be classified.



Notes to the Standalone Financial Statements for the year ended 31 March 2025

When measuring the fair value of a financial asset or a financial liability, the Company uses observable market data as far as possible. Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2B Material accounting policies:

The accounting policies set out below have been applied consistently to the periods presented in the financial statements.

a. Revenue recognition

The company derives revenues primarily from sale of goods comprising of Animal Feed Supplements and Agri Supplies.

The following is a summary of material accounting policies related to revenue recognition:

Revenue from contract with customers is recognised upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services.

Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer.

Revenue is measured based on the transaction price, which is the consideration, as specified in the contract with the customers.

Use of significant judgements in revenue recognition.

- Judgement is also required to determine the transaction price for the contract. The transaction price could be either a fixed amount of consideration or variable consideration with elements such as turnover/product/prompt payment discounts. Any consideration payable to the customer is adjusted to the transaction price, unless it is a payment for a distinct product or service from the customer. The estimated amount of variable consideration is adjusted in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur and is reassessed at the end of each reporting period.
- The Company exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time. The Company considers indicators such as how customer consumes benefits as services are rendered or who controls the asset as it is being created or existence of enforceable right to payment for performance to date and alternate use of such product or service, transfer of significant risks and rewards to the customer, acceptance of delivery by the customer, etc.

Interest income is recognized on a time proportionate basis, taking into account the amount outstanding and the rates applicable.

b. Property, plant and equipment and depreciation

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any. Cost includes taxes, duties, freight and other incidental expenses directly related to acquisition/construction and installation of the assets. Any trade discounts and rebates are deducted in arriving at the purchase price.

Subsequent expenditure related to an item of tangible assets are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Capital work-in-progress includes fixed assets not ready for their intended use and related incidental expenses and attributable interest.

iv. The estimated useful life of assets are as follows:

Building 30-60 years
Plant and equipment 15 years
Furniture and fixtures 10 years
Vehicles 8 years
Office equipment 5 years
Computer and data processing equipment 3 years



Notes to the Standalone Financial Statements for the year ended 31 March 2025

Depreciation on tangible assets other than plant and equipment has been provided on Written Down Value method and on plant and equipment on Straight Line Method. Depreciation is provided on a pro-rata basis, i.e. from the date on which asset is ready for use.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

An item of property, plant and equipment is eliminated from the financial statements on disposal or when no further benefit is expected from its use and disposal. Gains / losses arising from disposal are recognised in the Statement of Profit and Loss.

c. Impairment of Property, plant and equipments

The carrying values of assets at each balance sheet date are reviewed for impairment if any indication of impairment exists.

If the carrying amount of the assets exceed the estimated recoverable amount, an impairment is recognized for such excess amount. The impairment loss is recognized as an expense in the Statement of Profit and Loss, unless the asset is carried at revalued amount, in which case any impairment loss of the revalued asset is treated as a revaluation decrease to the extent a revaluation reserve is available for that asset.

The recoverable amount is the greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flows to their present value based on an appropriate discount factor.

When there is indication that an impairment loss recognized for an asset (other than a revalued asset) in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognized in the Statement of Profit and Loss, to the extent the amount was previously charged to the Statement of Profit and Loss. In case of revalued assets such reversal is not recognized.

d. Inventories

Stock in trade is valued at lower of cost and net reliasable value. Cost is determined on weighted average cost method, which is determined on their specific individual costs which includes only purchase cost.

e. Employee benefits

i. Employee benefits payable wholly within twelve months of receiving employees services are classified as short-term employee benefits. The short term employee benefits are accounted on undiscounted basis during the accounting period based on services rendered by employees.

ii. Defined contribution plans

 Λ defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts.

The Company contributes to statutory provident fund in accordance with Employees Provident Fund and Miscellaneous Provisions Act, 1952 that is a defined contribution plan and contribution paid or payable is recognized as an expense in the period in which the employee renders services.

Superannuation benefits, a defined contribution plan, has been funded with Life Insurance Corporation of India and the contribution is charged to Statement of profit and loss, when the contribution to the Fund is due.

iii. Defined benefit plans

The Company provides for gratuity benefit and compensated absences, which are defined benefit plans, covering all its eligible employees. Liability towards gratuity benefits and compensated absences expected to occur after twelve months, are determined using the Projected Unit Credit Method. Actuarial valuations are carried out at the balance sheet date. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in OCL. The retirement benefit obligation recognized in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognized past service cost, and as reduced by the fair value of scheme assets. The gratuity benefit and compensated absences scheme is funded with the Life Insurance Corporation of India (LIC).

The short term provision for compensated absences has been calculated on undiscounted basis, based on the balance of leave available over and above the maximum accumulation allowed as per the Company policy.

f. Income taxes

Income tax expense comprises current tax (i.e. amount of tax for the period determined in accordance with the income tax law), deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period)



Notes to the Standalone Financial Statements for the year ended 31 March 2025

g. Current tax

Current tax is computed and provided for in accordance with the applicable provisions of the Income Tax Act, 1961.

h. Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation.

i. Provisions and contingencies

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost.

A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but will probably not, require an outflow of resources. When there is a possible obligation of a present obligation in respect of which the likelihood of outflow of resources is remote, no provision disclosure is made.

j. Financial Instruments

a. Financial assets

i. Recognition and initial measurement

Trade receivables and debt instruments issued are initially recognised when they are originated. All other financial assets are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset is initially measured at fair value. In the case of financial assets which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the statement of profit and loss. In other cases, the transaction costs are attributed to the acquisition value of the financial asset.

ii. Classification

On initial recognition, a financial asset is classified as measured at

- amortised cost; or
- fair value through profit or loss (FVTPL); or
- fair value through other comprehensive income (FVOCI) debt investment or equity investment

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at FVTPL:

- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.



Notes to the Standalone Financial Statements for the year ended 31 March 2025

A debt investment is measured at FVOCI if it meets both of the following conditions and is not designated as at FVTPL:

- the asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

iii Subsequent measurement and gains and losses

Financial assets at FVTPL

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial assets at amortised cost

These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

iv. Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

v. Impairment of financial assets

In accordance with Ind AS 109, the company applies Expected Credit Loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

. Financial assets that are debt instruments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance.

ii Trade receivables.

The application of simplified approach does not require the company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

b. Financial liabilities

i. Recognition and initial measurement

All financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial liability is initially measured at fair value. In the case of financial liabilities which are recognised at fair value through profit and loss (FVTPL), the transaction costs are recognised in the statement of profit and loss. In other cases, the transaction costs are attributed to the acquisition or issue of financial liability.

ii Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held- for- trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

iii. Derecognition

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire.



Notes to the Standalone Financial Statements for the year ended 31 March 2025

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in profit or loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

k. Foreign Currency Transactions

The Financial Statements of Company are presented in INR, which is also its functional currency. In preparing the Financial Statements, transactions in currencies other than the entity's functional currency are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at that date. Non-monetary items denominated in foreign currency are reported at the exchange rate ruling on the date of transaction.

Exchange differences on monetary items are recognised in the Statement of Profit & Loss in the period in which they arise.

2C Recent accounting pronouncements

The Ministry of Corporate Affairs (MCA) notifies new standard for amendments to the existing standards. There is no such notifications which would have been applicable from 1st April 2025.



Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Notes to the Standalone Financial Statements for the year ended 31 March 2025

(Rs in millions)

3 Property, Plant and Equipment

| Gross block | Land | Buildings | Plant | Office | Furniture | Vehicles | Computers | Total |
|---|----------|-----------|-------|------------|--------------|----------|-----------|-------|
| | Freehold | 1 | | Equipments | and fixtures | | 1 | |
| Balance as at 31 March 2023 | 1.45 | 20.55 | 0.29 | 0.65 | 3.15 | 8.91 | 1.26 | 36.26 |
| Additions | , | ı | 1 | , | , | ı | 0.03 | 0.03 |
| Disposal | ı | ı | ٠ | ı | • | • | | ı |
| Balance as at 31 March 2024 | 1.45 | 20.55 | 0.29 | 0.65 | 3.15 | 8.91 | 1.30 | 36.29 |
| .Additions | ı | 1 | 1 | ı | ı | 1.60 | 0.09 | 1.69 |
| Disposal | 1 | 1 | 1 | • | 1 | 1.19 | • | 1.19 |
| Balance as at 31 March 2025 | 1.45 | 20.55 | 0.29 | 0.65 | 3.15 | 9.32 | 1.39 | 36.80 |
| Accumulated depreciation and amortisation | | | | | | | | |
| Balance as at 31 March 2023 | | 6.52 | 0.08 | 0.51 | 2.76 | 3.33 | 0.84 | 14.04 |
| Depreciation and amortisation | ι | 0.74 | 0.02 | 0.05 | 0.10 | 1.71 | 0.23 | 2.81 |
| Balance as at 31 March 2024 | • | 7.26 | 0.10 | 0.53 | 2.86 | 5.04 | 1.07 | 16.85 |
| Depreciation and amortisation | • | 0.69 | 0.02 | 0.01 | . 0.04 | 1.20 | 0.12 | 2.08 |
| Reversal on disposal of asset | r | • | 1 | • | 1 | 1.13 | 1 | 1.13 |
| Balance as at 31 March 2025 | | 7.95 | 0.12 | 0.54 | 2.90 | 5.11 | 1.18 | 17.80 |
| Balance as at 31 March 2024 | 1.45 | 13.29 | 0.18 | 0.12 | 0.29 | 3.88 | 0.23 | 19.44 |
| Balance as at 31 March 2025 | 1.45 | 12.60 | 0.17 | 0.11 | 0.26 | 4.22 | 0.20 | 18.99 |

Notes:

1 Title deeds of Freehold Land and building are held in the name of the Company.



| Notes to the Standalone Financial Statements for the year ended 31 March 2025 | , |
|---|---|
| | |

| .5 | In M | illions |
|--|--|---------------|
| | 31 March 2025 | 31 March 2024 |
| 4 Deferred Tax Asset (net) | | 10 |
| Deferred tax liabilities | | |
| Arising on account of timing difference in: | | |
| Property, plant and equipment | 0.48 | 0.43 |
| Fair Value Changes | 0.63 | - |
| | 1.11 | 0.43 |
| Deferred tax assets | | |
| Arising on account of timing difference in: | | |
| Deferred Income | 0.73 | 0.70 |
| Employee benefits | 0.45 | (0.08 |
| Trade receivables | 2.17 | 1.42 |
| | 3.35 | 2,04 |
| Deferred Tax Assets (Net) | 2.24 | 1.61 |
| 5 Non-current assets | | |
| Unsecured, considered good | | |
| | 0.30 | 0.30 |
| - Security Deposit | 0.30 | 0.30 |
| | 0.30 | 0.30 |
| 6 Inventories | | |
| At lower of cost and net realisable value | | |
| Stock-in-trade | 6.76 | 3.95 |
| CHOCK-III-LIAME | 6.76 | 3.95 |
| | | |
| 7 Current Investments | | |
| Investments in mutual funds at Fair Value through Profit and Loss | | |
| Unquoted fully paid-up | | |
| Income Plan: Growth Option | 42.48 | 59.60 |
| | 42.48 | 59.60 |
| 8 Trade Receivables | | |
| Unsecured | | |
| - Considered good | 120.02 | 121.95 |
| Credit impaired | 120102 | 121155 |
| - Considered doubtful | 8.63 | 5.65 |
| « Consucred doubten | 128.65 | 127.60 |
| | | |
| Less: Impairment position on Expected Credit Loss Model | 8.63 | 5.65 |
| Annual Control of the | 120.02 | 121.95 |
| | | |
| | 120.02 | 121.95 |
| (Refer note 32 for information about credit risk and market risk of trade receivables) | | 12 |
| Trade Receivables ageing schedule- | | |
| Trade Receivables ageing schedule- | Outstanding for following periods from due date of payment | |
| In the second second | Sustaining for following periods from due date of payment | 41 |

| | | Outst | anding for follo | wing periods fro | m due date of p | ayment | THE STATE OF THE S |
|--|---------|-----------------------|---------------------|------------------|-----------------|-----------|--|
| Particulars | Not Due | Less than 6 months | 6 months -1 year | 1-2 years | 2-3 years | > 3 years | Total |
| As at March 31, 2025 | | | | | - | | |
| (i) Undisputed Trade receivables – considered good | 97.44 | 19.57 | 0.42 | 0.97 | 0.71 | 0.90 | 120.02 |
| (ii) Undisputed Trade Receivables - which have significant increase in credit risk | 0.45 | 1.19 | 0.22 | 1.39 | 2.36 | 3.02 | 8.63 |
| Total | 97.89 | 20.76 | 0.64 | 2.36 | 3.07 | 3.92 | 128.65 |
| As at March 31, 2024 | | | | | | | |
| (i) Undisputed Trade receivables – considered good | 99.66 | 17.99 | 1.89 | 2.40 | ¥8 | | 121.95 |
| (ii) Undisputed Trade Receivables - which have significant increase in credit risk | 0.41 | 0.52 | 0.32 | 1.30 | 1.58 | 1.52 | 5.65 |

| Total | 100.06 | 18.52 | 2.21 | 3.70 | 1.58 | 1.52 | 127.60 |
|--|--------|-------|------|------|------|------|--------|
| (ii) Undisputed Trade Receivables – which have significant increase in credit risk | 0.41 | 0.52 | 0.32 | 1.30 | 1.58 | 1.52 | 5.65 |
| As at March 31, 2024 (i) Undisputed Trade receivables – considered good | 99.66 | 17.99 | 1.89 | 2.40 | ¥ | - | 121.9 |

| 9 | Cash and Cash Equivalents |
|---|---|
| | Cash and Cash Equivalents (as per IND AS-7 - "Statement of Cash Flows") |
| | Balances with banks |

| - in current accounts | 17.49 | 14.79 |
|-----------------------|-------|-------|
| Cash on hand | 0.00 | 0.00 |
| | 17.49 | 14.80 |

| Other bank balances | | |
|---|-------|-------|
| Deposits with maturity more than three months but less than twelve months | 45.00 | 45.00 |
| | 45.00 | 45.00 |

| Deposits with maturity more than three months but less than twerve months | 45.00 | 43.00 |
|---|-------|-------|
| | 45.00 | 45.00 |
| | 62.49 | 59.80 |

0.77

0.59

| 10 | Current Loans |
|----|-----------------------|
| | Unanamed and Handwood |

| | | | 62.49 | 59.80 |
|------------------|--|--|-------|-------|
| | | | | |
| 10 Current Loans | | | | |
| to Current Louis | | | | |



Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Notes to the Standalone Financial Statements for the year ended 31 March 2025

11 Other current financial assets Interest receivable Security deposit



| In Mi | llions |
|---------------|---------------|
| 31 March 2025 | 31 March 2024 |
| 0.77 | 0.59 |
| 1.70 | 1.74 |
| - | - |

Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Notes to the Standalone Financial Statements for the year ended 31 March 2025

| 2 Other Current Assets | |
|---|--|
| Prepaid expenses | |
| Advance to suppliers | |
| Balance with revenue authorities | |
| Others | |
| Excess of Planned Assets over Obligation-Gratuity | |

| 31 March 2025 | 31 March 2024 |
|---------------|---------------|
| 51 March 2025 | 31 March 2024 |
| 0.50 | 0.47 |
| 2.73 | 5.63 |
| (0.00) | 0.02 |
| 1.37 | |
| 0.68 | 0.82 |
| 5.28 | 6.94 |



icial Statements for the year ended 31 March 2025 No

| | In M | illions |
|---|--|---------------|
| | 31 March 2025 | 31 March 2024 |
| 13 Equity Share Capital | | |
| Authorised | | |
| 1,00,000 Equity Shares of Rs.10/- each | 1.00 | 1.00 |
| Issued, Subscribed & Paid up | | |
| 1,00,000 Equity Shares of Rs.10/- each | 1.00 | 1,00 |
| Reconciliation of Equity share capital | No. of shares | No. of shares |
| Shares outstanding at the beginning of the Year | 0.10 | 0.10 |
| Shares Issued during the year | 57 | 5.7 |
| Shares bought back during the year | (Control of the Control of the Contr | - |
| Shares outstanding at the end of the year | 0.10 | 0.10 |

Rights, preferences and restrictions attached to shares;

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. The Dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except is case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

- b) Out of the total 1,00,000 shares, 60,000 shares are held by Advanced Enzyme Technologies Ltd, the holding company.
- Particulars of shareholders holding more than 5%

| | As at 31 M | As at 31 | | | |
|--|-----------------------|-----------------|------------------|--------------|--------------|
| Name of Shareholder | No. of Shares held | % of Holding | No. of Shares | % of Holding | % of Holding |
| M/s. Advanced Enzyme Technologies Ltd and its nominees | 60,000 | 60% | 60,000 | 60% | 60% |
| Mr. Omprakash B. Singh | 40,000 | 40% | 40,000 | 40% | 40% |

d) During the year ended 31 March 2025, the amount of per share dividend recognized as distributions to equity shareholders was Rs. 400/- (31 March 2024 Rs. 200/-)

Details of Charge hold by Dromotors at the end of the year

| Annual Control of the | As at 31 M | As at 31 March 2025 A | | As at 31 March 2024 | | As at 31 March 2023 | |
|--|------------------|-----------------------|------------------|---------------------|---------------|----------------------|-----------------------------------|
| Promoter name | No. of Shares | % of total shares | No. of Shares | % of total shares | No. of Shares | % of total shares | between 31 Mar 25 vs 31 Mar 24 |
| M/s. Advanced Enzyme Technologies Ltd and its nominees | 60,000 | 60% | 60,000 | 60% | 60,000 | 60% | 0% |
| Mr. Omprakash B. Singh | 40,000 | 40% | 40,000 | 40% | 40,000 | 40% | 0% |

| 4 Other Equity | In N | Aillions |
|--|---------------|---------------|
| ,, | 31 March 2025 | 31 March 2024 |
| General Reserve | V | |
| Balance as per last Balance Sheet. | 6.23 | 6.23 |
| Add: Transferred from Statement of Profit and Loss | | - |
| Closing Balance | 6.23 | 6.23 |
| Retained earnings | | |
| Balance as per last accounts. | 228.35 | 207.92 |
| Profit for the year | 36.31 | 40.42 |
| (-) Interim Dividend at Rs. 400 per share | (40.00 | (20.00 |
| | 224.66 | 228.35 |
| Total | 230.89 | 234.58 |
| | | |

| 15 Borrowings | | In Mil | lions | In Mill | ions |
|-----------------------------|-----|-------------|---------|-------------|---------|
| | | 31 Marc | h 2025 | 31 March | 2024 |
| | 12 | Non-current | Current | Non-current | Current |
| Secured | 190 | | | | |
| Term loans Vehicle loans | | 1.53 | 1.44 | 2.97 | 1.34 |
| Total borrowings | | 1.53 | 1.44 | 2.97 | 1.34 |

a) Details of security for each type of borrowings
 (i) Term loans from banks taken for purchase of vehicle are specifically secured by
 1. Secured by Specified fixed assets exclusively charged in Hire purchase agreement taken from the HDFC Bank repayable in 60 equated monthly instalments at the interest rate of 6.80%

| 16 Trade Payables | In Mi | illions |
|--|---------------|---------------|
| | 31 March 2025 | 31 March 2024 |
| Total outstanding dues to micro and small enterprises Total outstanding dues to others | 10.30 | 19.60 |
| | 10.30 | 19.60 |



Notes to the Standalone Financial Statements for the year ended 31 March 2025

Trade Payables ageing schedule

| | Outstanding for following periods from due date of payment | | | | | | | |
|----------------------|--|---------------------|-----------|-----------|----------------------|---|----|-------|
| Particulars | Not Due | Less than 1 year | 1-2 years | 2-3 years | More than 3 years | | | Total |
| As at March 31, 2025 | | | | | | | | |
| i) MSME | | | - | | | 9 | | - |
| ii) Others | 10.30 | | | | | - | | 10.30 |
| Total | 10.30 | | 25 | 320 | 2 | | 2 | 10.30 |
| As at March 31, 2024 | | | | | | | | |
| i) MSME | 140 | S S | - | - | 8 | 4 | 92 | - |
| ii) Others | 19.60 | 12 | | (4) | 32 | | 32 | 19.60 |
| Total | 19.60 | - | - | 1.00 | | - | - | 19.60 |

| 17 Current- Other Financial Liabilities | In N | Aillions |
|---|---------------|---------------|
| | 31 March 2025 | 31 March 2024 |
| Advance from customers | 0.03 | 0.41 |
| Security deposits from customers | 0.50 | 0.50 |
| Employee benefits payable | 9.39 | 6.58 |
| | 9.92 | 7,49 |
| 18 Other Current Liabilities | In N | Aillions |
| | 31 March 2025 | 31 March 2024 |
| Provident fund | 0.15 | 0.16 |
| Other statutory dues | 1.29 | 1.25 |
| Other payables | 13.59 | 15.78 |
| | 15.07 | 17.19 |
| 19 Current Provisions | In N | Aillions |
| | 31 March 2025 | 31 March 2024 |
| Provision for employee benefits (refer note 30) | | |
| Compensated Absences (funded) | 1.11 | 1.39 |
| | 1.11 | 1.39 |



Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Notes to the Standalone Financial Statements for the year ended 31 March 2025 Rs in millions Year ended 31 Year ended 31 March 2025 March 2024 20 Revenue from contracts with customers 461.80 429.90 Sale of products Domestic 17.02 Exports 18:37 478.82 448.27 Details of products sold - Traded goods - Animal feed supplements 475.29 444.98 3.53 3.28 - Agri Supplies 478.82 448.27 21 Other Income Duty Drawback 0.07 0.01 Interest income on Bank Fixed Deposits 3.34 3.23 Interest on Income Tax Refund 0.21 Exchange fluctuation 0.03 0.12 Sundry balances written back 0.00 0.53 Income on Financial assets carried at fair value through profit or loss - Net gain on fair value changes of Current Investments 2.51 2.12 - Net gain on sale of Current Investments 1.31 1.23 Gain from sale of Property, Plant & Equipment 0.12 0.23 0.06 Miscellaneous income 7.82 7.30 22 Purchases of Stock-in-Trade 304.13 279.24 Purchases - Animal Feed Supplies Purchases - Agri Supplies 1.31 1.71 305.44 280.95 23 Changes in inventories of finished goods and work-inprogress Closing Stock Stock-in-trade 6.76 3.95 Less: Opening Stock Stock-in-trade 3.95 5.66 (2.81)1.71 24 Employee Benefits Expense Salaries, Wages & Bonus 49.72 46.07 Contribution to provident and other funds 2.20 2.08 Retirement benefits expense 0.54 0.55 Staff welfare expenses 3.37 2.69 55.84 51.38



Advanced Bio-Agro Tech Limited CIN: U24100MH2004PLC149464 Notes to the Standalone Financial Statements for the year ended 31 March 2025 Rs in millions Year ended 31 Year ended 31 March 2025 March 2024 25 Finance Costs Interest expense 0.27 0.36 0.20 Bank charges 0.14 0.47 0.50 26 Other Expenses 0.81 0.79 Insurance 3.61 3.61 Rates and taxes Printing and stationery 0.80 1.45 Legal and professional fees 12.03 10.91 Auditors' remuneration Audit fees 0.25 0.19 Repairs and maintenance 0.31 0.57 15.84 Travel and conveyance expenses 14.52 Communication 1.17 1.32 Commission on sales 2.55 0.21 Sales promotion and advertisement 6.12 3.62 Freight outward and forwarding 17.37 14.84 Other selling and distribution expenses 7.51 4.57 Provision for expected credit loss 2.98 3.37 4.63 Bad debts written off 0.18 Less: Provision for doubtful debts -4.55 0.18 0.08 Corporate social responsibility expenses (refer note no 35) 1.53 1.56 General expense 1.65 1.70

74.71

63.31



Notes to the Standalone Financial Statements for the year ended 31 March 2025

(Rs in Millions)

27 Segment Reporting - Disclosures under Ind AS 108 - "Operating Segment":

| i. | Entity wide disclosure | required by | Ind AS 108 | are as detailed below: |
|----|------------------------|-------------|------------|------------------------|
|----|------------------------|-------------|------------|------------------------|

| • | Year ended 31 March 2025 | Year ended 31 March 2024 |
|---|-----------------------------|-----------------------------|
| Bio- chemicals | 478.82 | 448.27 |
| Others | | - |
| | 478.82 | 448.27 |
| | | |

ii. Geographic information

The geographic information analyses the Company's revenues and non-current assets by the Company's country of domicile and other countries. In presenting geographic information, segment revenue has been based on the selling location in relation to sales to customers and segment assets are based on geographical location of assets.

| | | Y | ear ended | Year ended |
|--|--|------|------------|---------------|
| | | 31 M | larch 2025 | 31 March 2024 |
| a. Revenue from external custome | ers | | | |
| Within India | | | 461.80 | 429.90 |
| Outside India | 0. | | 17.02 | 18.37 |
| | | | 478.82 | 448.28 |
| | | 31 M | larch 2025 | 31 March 2024 |
| Non-current assets (other than | financial instruments and deferred tax assets) | | | |
| Within India | | | 18.99 | 19.44 |
| Outside India | | | - | 100 |
| | | | 18.99 | 19.44 |

iii. Maior customer

Revenue from one customer based in India represented Rs. 129.94 million (previous year Rs. 140.09 million) out of the total revenues.

28 Disaggregation of revenue

The management determines that the segment information reported under Note 27 Segment reporting is sufficient to meet the disclosure objective with respect to disaggregation of revenue under Ind AS 115 Revenue from contract with Customers. Hence, no separate disclosures of disaggregated revenues are reported.

29 Earnings per share (EPS)

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of Equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of Equity shares outstanding during the year plus the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

| | | 31 March 2025 | 31 March 2024 |
|--|------------|---------------|---------------|
| Profit attributable to equity holders | In Million | 36.27 | 40.24 |
| Weighter Average Number of equity shares (Face Value Rs. 10/-) | In Nos. | 100,000 | 100,000 |
| Basic earnings per share | In INR | 362.65 | 402.38 |
| Diluted earnings per share | In INR | 362.65 | 402.38 |



Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Notes to the Standalone Financial Statements for the year ended 31 March 2025

30. Post-Employment Benefits

(Rs in Millions)

The Company contributes to the following post-employment plans in India.

Defined Benefit Plan:

The Company provides for gratuity benefit and compensated absences, which are defined benefit plans, covering all its eligible employees. The Company has taken a group gratuity and compensated absences policy for its employees with the Life Insurance Corporation of India (LIC). Under gratuity policy, the eligible employees are entitled to receive gratuity payments upon their resignation or death (subject to completion of 4.5 years of employment) in lumpsum after deduction of necessary taxes.

This plan exposes the Company to actuarial risks such as longetivity risk, interest rate risk and market (investment) risk.

Based on the actuarial valuation obtained in this respect, the following table sets out the details of the employee benefit obligation and the plan assets as at balance sheet.

| | 31 | March 2025 | 31 Mai | rch 2024 |
|---|----------|----------------------|----------|----------------------|
| | Gratuity | Compensated absences | Gratuity | Compensated absences |
| Defined benefit obligation | (4. | 06) (3.42) | (4.17) | (3.19) |
| Fair value of plan assets | 4 | 74 2.31 | 5.00 | 1.80 |
| Net defined benefit (obligation)/assets | 0. | 68 (1.11) | 0.82 | (1.39) |
| | | | | |

i) Reconciliation in present value of obligations ('PVO') - defined benefit obligation:

| | | Defined benefit obligation | | | | |
|-------------------------------------|----------|----------------------------|---------------|------------------|--|--|
| | 31 Mar | ch 2025 | 31 March 2024 | | | |
| | Gratuity | Compensated | Gratuity | Compensated | | |
| Opening balance | 4.17 | absences 3.19 | 3.92 | absences 3.85 | | |
| Included in profit or loss | | | | | | |
| Current service cost | 0.63 | 0.62 | 0.61 | 0.29 | | |
| Interest cost | 0.30 | 0.19 | 0.29 | 0,22 | | |
| | 5.09 | 4.00 | 4.82 | 4.36 | | |
| Included in OCI | (0.04) | 0.27 | (0.25) | (0.36) | | |
| Remeasurement loss (gain): | | | | | | |
| Actuarial loss (gain) arising from: | | | | | | |
| Demographic assumptions | 10 | - | 121 | 2 | | |
| Financial assumptions | 0.17 | 0.10 | 0.06 | 0.03 | | |
| Experience adjustment | (0.21) | 0.17 | (0.31) | (0.40) | | |
| | 5.05 | 4.27 | 4.57 | 4.00 | | |
| Benefits paid | (1.00) | (0.85) | (0.39) | (0.81) | | |
| Benefits Payable | Sec. 100 | | | | | |
| Closing balance | 4.05 | 3.42 | 4.17 | 3.19 | | |

ii) Change in fair value of plan assets

| ii) Change in lan value of plan assets | Fair value o | f plan assets | Fair value o | of plan assets | | |
|--|--------------|---------------|--------------|----------------|--|--|
| | - | 31 March 2025 | | 31 March 2024 | | |
| | Gratuity | | | Compensated | | |
| | | absences | | absences | | |
| Opening balance | 5.00 | 1.80 | 4.53 | 1.61 | | |
| Included in profit or loss | | | | | | |
| Expected return on plan assets | 0.38 | 0.09 | 0.35 | 0.07 | | |
| | 5.38 | 1.89 | 4.88 | 1.68 | | |
| Included in OCI | 0.04 | 0.06 | 0.01 | 0.06 | | |
| Remeasurement loss (gain): | | | | | | |
| Actuarial loss (gain) arising from: | | | | | | |
| Experience adjustment | 0.04 | 0.06 | 0.01 | 0.06 | | |
| | 5.42 | 1.96 | 4.89 | 1.73 | | |
| Other | | | | | | |
| Contributions paid by the employer | 0.33 | 0.35 | 0.21 | 0.07 | | |
| Benefits paid | (1.00) | 7 | (0.10) | | | |
| Closing balance | 4.74 | 2.31 | 5.00 | 1.80 | | |



Notes to the Standalone Financial Statements for the year ended 31 March 2025

30. Post-Employment Benefits

iii) Expense recognised in the Statement of Profit and Loss:

(Rs in Millions)

| | 31 March 2025 | | 31 Mar | ch 2024 |
|---|---------------|----------------------|----------|----------------------|
| | Gratuity | Compensated absences | Gratuity | Compensated absences |
| Current service cost | 0.63 | 0.62 | 0.61 | 0.29 |
| Interest cost | (0.08) | 0.10 | (0.07) | 0.15 |
| Net value of remeasurements on the obligation and plan assets | - | 0.21 | | (0.42) |
| Total expense recognised in the Statement of Profit and Loss | 0.55 | 0.93 | 0.54 | 0.02 |

iv) Other Comprehensive Income:

| | | 31 March 2025 | 31 March 2024 | |
|--|----|---|---------------|--|
| | 10 | 31 March 2025 Gratuity 0.17 (0.21) (0.04) | Gratuity | |
| Actuarial loss / (gain) from: | | | | |
| -Demographic assumptions | | | - | |
| -Financial assumptions | | 0.17 | 0.06 | |
| -Experience adjustment | | (0.21) | (0.31) | |
| Return on plan assets excluding net interest | | (0.04) | (0.01) | |
| Total amount recognised in OCI | | (0.08) | (0.26) | |

v) Actuarial assumptions

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages):

| | 31 Mar | 31 March 2025 | | 31 March 2024 | | |
|-------------------------------|---|---|----------|------------------------|--|--|
| | Gratuity | Compensated | Gratuity | Compensated | | |
| | proof and Market and Mark | absences | | absences | | |
| Policy of insurance | 100% | 100% | 100% | 100% | | |
| Discount rate | 6.70% | 6.70% | 7.20% | 7.20% | | |
| Rate of return on plan assets | 6.70% | 6.70% | 7.20% | 7.20% | | |
| Salary Escalation | 8.00% | 8.00% | 8.00% | 8.00% | | |
| Withdrawal rates | 5% p.a. at younger ages reducing to 1% 5% p.a. at younger a | | | es reducing to 1% p.a. | | |
| | p.a. at o | lder ages | at old | er ages | | |
| Leave availment rates | - | 0.50% | | 0.50% | | |
| Retirement age | 58 y | 58 years | | years | | |
| Mortality rates | • | As published under the Indian assured lives mortality (2012-14) table | | | | |

Assumptions regarding future mortality have been based on published statistics and mortality tables.

vi) Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below.

| | 31 Marc | 31 March 2024 | | |
|---------------------------------------|----------|---------------|----------|----------|
| | Increase | Decrease | Increase | Decrease |
| Discount rate (0.50% movement) | 3.32 | 3.53 | 3.11 | 3.28 |
| Future salary growth (0.50% movement) | 3.53 | 3.32 | 3.28 | 3.11 |
| Withdrawal rate (10% movement) | 3.41 | 3.43 | 3.19 | 3.20 |

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occuring at the end of the reporting period.

vii) Expected future cash flows

The expected future cash flows in respect of gratuity as at 31 March 2025 were as follows: The expected contributions for defined benefit plan for the next financial year will be Rs. 7,56,698/-

Expected future benefit payments

| Expected future benefit paymen | 113 | |
|--------------------------------|-----|------|
| 31 March 2026 | | 0.76 |
| 31 March 2027 | | 80.0 |
| 31 March 2028 | | 0.08 |
| 31 March 2029 | | 0.09 |
| 31 March 2030 | | 0.28 |
| Therafter | | 2.85 |
| | | |



Notes to the Standalone Financial Statements for the year ended 31 March 2025

| 31 Income | taxes |
|-----------|-------|
|-----------|-------|

(Rs in Millions)

| Allers | | | |
|--------|----|-----|----|
| Tax | ex | реп | se |

| | Year ended 31 March 2025 | Year ended 31 March 2024 |
|---|-----------------------------|-----------------------------|
| Current income tax | 13.3 | 13.22 |
| Changes in estimates related to prior period | 1.9 | 0.54 |
| | 15.2 | 13.77 |
| Deferred income tax liability / (asset), net | | |
| Origination and reversal of temporary differences | (0.65 | 0.91 |
| Deferred tax expense | (0.65 | 0.91 |
| Tax expense for the year | 14.6 | 14.68 |

(b) Amounts recognised in other comprehensive income

| | Yea | Year ended 31 March 2025 | | | Year ended 31 March 2024 | | |
|---|------------|--------------------------|------------|------------|--------------------------|------------|--|
| | Before tax | Tax (expense) benefit | Net of tax | Before tax | Tax (expense) benefit | Net of tax | |
| Items that will not be reclassified to profit or loss | 8 | * | | | | | |
| Remeasurement of Defined Benefit Plans | (0.08) | 0.02 | (0.05) | (0.26) | 0.07 | (0.20) | |
| | (0.08) | 0.02 | (0.05) | (0.26) | 0.07 | (0.20) | |

| 1.1 | Reconci | 11 | C - CC | a factor and | CONTRACTOR OF THE PARTY OF THE |
|-----|---------|----|--------|--------------|---|
| | | | | | |

| | Year ended 31 March 2025 | Year ended 31 March 2024 |
|--|-----------------------------|-----------------------------|
| Profit before tax | 50.90 | 54.90 |
| Tax using the Company's domestic tax rate (31 March 2025: 25.17%, 31 March 2024: 25.17%) | 12.81 | 13.82 |
| Tax effect of: | | |
| Permanent differences | 0.39 | 0.41 |
| Expenses allowable on payment basis | (0.49) | 0.84 |
| Income not chargeable to Tax | | 72 |
| Others | 2.58 | (1.30) |
| Tax expense as per profit or loss | 15.29 | 13.77 |

(d) Movement in deferred tax balances

| | 31 March 2025 | | | | | | |
|-------------------------------|-----------------------------|---------------------------------|----------------------|---------------------------------------|-----------------------|---------------------------|--|
| Particulars | Net balance 1 April 2024 | Recognised in profit or loss | Recognised in OCI | Net deferred tax (asset)/liability | Deferred tax asset | Deferred tax liability | |
| Property, plant and equipment | 0.43 | 0.05 | * | 0.48 | * | 0.48 | |
| Fair Value Changes | 0.53 | 0.10 | 2 | 0.63 | 2 | 0.63 | |
| Deferred Income | (0.70) | (0.03) | | (0.73) | (0.73) | 1 1/2 | |
| Employee benefits | (0.45) | (0.01) | (0.02) | (0.45) | (0.45) | * | |
| Trade receivables | (1.42) | (0.75) | W ₂ 18 | (2.17) | (2.17) | - | |
| Tax assets (Liabilities) | (1.61) | (0.65) | (0.02) | (2.24) | (3.35) | 1.11 | |

| | | | 31 Ma | rch 2024 | | |
|-------------------------------|-----------------------------|---------------------------------|----------------------|---------------------------------------|-----------------------|---------------------------|
| Particulars | Net balance 1 April 2023 | Recognised in profit or loss | Recognised in OCI | Net deferred tax (asset)/liability | Deferred tax asset | Deferred tax liability |
| Property, plant and equipment | 0.54 | (0.11) | * | 0.43 | | 0.43 |
| Fair Value Changes | (0.03) | 0.57 | | 0.53 | | 0.53 |
| Deferred Income | (0.67) | (0.03) | - | (0.70) | (0.70) | - |
| Employee benefits | (0.71) | 0.19 | 0.07 | (0.45) | (0.45) | * |
| Trade receivables | (1.72) | 0.30 | | (1.42) | (1.42) | 2 |
| Tax assets (Liabilities) | (2.58) | 0.91 | 0.07 | (1.61) | (2.57) | 0.97 |

The company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

Significant management judgement is required in determining provision for income tax, deferred income tax assets and liabilities and recoverability of deferred income tax assets. The recoverability of deferred income tax assets is based on estimates of taxable income and the period over which deferred income tax assets will be recovered. Any changes in future taxable income would impact the recoverability of deferred tax assets.



Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Notes to the Standalone Financial Statements for the year ended 31 March 2025

32. Financial instruments

(Rs in Millions)

Fair Values and Hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are a) recognised and measured at fair value and b) measured at amortised cost and for which fair values are disclosed in the Standalone Financial Statements. To provide an indication about the reliability of the inputs used in determining fair value, the Company has classified its financial instruments into the three levels prescribed in the Indian Accounting Standard.

| Particulars | Hierarchy | Fair Value/Carrying Value | | |
|-------------|-----------|---------------------------|---------------|--|
| | | 31 March 2025 | 31 March 2024 | |
| Investments | Level 1 | 42.48 | | |

Level 3: Fair value of financial assets and liabilities measured at amortised cost

| Particulars | | Note No. | Fair Value/Carrying Value | |
|-----------------------------|----|----------|---------------------------|---------------|
| | | | 31 March 2025 | 31 March 2024 |
| Financial assets | | | | |
| Loans | 19 | 10 | 0.77 | 0.59 |
| Others | | 11 | 1.70 | 1.74 |
| | | | 2.46 | 2.33 |
| Financial liabilities | | | | |
| Borrowings | | 15 | 2.96 | 4.31 |
| Other financial Liabilities | | 17 | 9.92 | 7.49 |
| | | | 12.88 | 11.80 |

Note: There have been no transfers among Level 1, Level 2 and Level 3 during the year.

The carrying amounts of trade receivables, cash and cash equivalents, other bank balances and trade payables are considered to be the same as their fair values due to the current and short-term nature of such balances.

B. Measurement of fair values

The following tables show the valuation techniques used in measuring Level 1, Level 2 and Level 3 fair values, as well as the significant unobservable inputs used:

Financial instruments measured at fair value

| Туре | Valuation technique | | | | |
|---|--|--|--|--|--|
| Non current financial assets / liabilities measured at amortised cost | Discounted cash flow technique: The valuation model considers present value of expected payments discounted using an appropriate discounting rate. | | | | |
| Non current financial assets / liabilities measured at FVTPL | This includes financial instruments measured using quoted prices. The fair value of all equity instruments which are traded on the Stock Exchanges is valued using the closing price as at the reporting period. | | | | |



Notes to the Financial Statements for the year ended 31 March 2025

(Rs in Millions)

Financial instruments - Fair values and risk management

C. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- " Credit risk ;
- · Liquidity risk; and
- · Market risk

i. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

ii. Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of incurred losses in respect of trade and other receivables and investments.

Trade and other receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.

At 31 March 2025, the Company's most significant customer accounted for INR 14.22 million of the trade and other receivables carrying amount (31 March 2024: INR 37.49 million).

Summary of the Company's exposure to credit risk by age of the outstanding from various customers is as follows:

| | | 31 March 2025 | |
|--------------------|-----------------|-------------------------------|----------------|
| | Carrying Amount | Weighted Average Loss Rate | Loss Allowance |
| Not due | 97.89 | 0.5% | 0.45 |
| 0-90 days | 13.81 | 2.2% | 0.30 |
| 90-180 days | 6.95 | 12.8% | 0.89 |
| 180-270 days | 0.57 | 33.6% | 0.19 |
| 270-360 days | 0.07 | 42.1% | 0.03 |
| More than 360 days | 9.35 | 72.4% | 6.77 |
| Ē/ | 128.65 | | 8.63 |

| | | | | 31 March 2024 | | |
|---|--|--|---|-----------------|------------------|----------------|
| | | | | Carrying Amount | Weighted Average | Loss Allowance |
| | | | 9 | | Loss Rate | |
| Not due | | | | 99.66 | 0.4% | 0.41 |
| 0-90 days | | | | 15.14 | 1.8% | 0.27 |
| 90-180 days | | | | 2.85 | 8.8% | 0.25 |
| 180-270 days | | | | 1.32 | 15.3% | 0.20 |
| 270-360 days | | | | 0.58 | 20.5% | 0.12 |
| More than 360 days | | | | 8.05 | 54.6% | 4.40 |
| \$100 C 100 C | | | | 127.60 | | 5.65 |

Expected credit loss assessment for customers as at 31 March 2025 and 31 March 2024

The Company allocates each exposure to a credit risk grade based on a variety of data that is determined to be predictive of the risk of loss (e.g. timeliness of payments, available press information etc.) and applying experienced credit judgement.

| | 31 March 2025 | 31 March 2024 |
|------------------------------------|---------------|---------------|
| Opening Balance | 5.65 | 6.83 |
| Impairment loss created/(reversed) | 2.98 | 3.37 |
| Amounts written off | 740 | 4.55 |
| Closing Balance | 8.63 | 5.65 |

The Company held cash and cash equivalents of INR 17.49 million at 31 March 2025 (31 March 2024: INR 14.80 million). The cash and cash equivalents are held with bank and financial institution counterparties with good credit ratings.

Investments

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.

Other than trade and other receivables, the Company has no other financial assets that are past due but not impaired.



Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Notes to the Financial Statements for the year ended 31 March 2025

(Rs in Millions)

Financial instruments – Fair values and risk management iii. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company has obtained fund and non-fund based working capital lines from various banks. The Company invests its surplus funds in bank fixed deposit which carry no/low mark to market risks. The Company monitors funding options available in the debt and capital markets with a view to maintaining financial flexibility.

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments.

| 31 March 2025 | Carrying amount | Total | Upto 1 year | 1-3 years | 3-5 years |
|-----------------------------|-----------------|-------|-------------|-----------|-----------|
| Long term borrowings | 1.53 | 1.53 | * | 1.54 | |
| Short term borrowings | 1.44 | 1.44 | 1.44 | | |
| Trade payable | 10.30 | 10.30 | 10.30 | - | |
| Other financial liabilities | 9.92 | 9.92 | 9.92 | (2) | - |

| 31 March 2024 | Carrying amount | Total | Upto 1 year | 1-3 years | 3-5 years |
|-----------------------------|-----------------|-------|-------------|-----------|-----------|
| Long term borrowings | 2.97 | 2.97 | | 2.97 | |
| Short term borrowings | 1.34 | 1.34 | 1.34 | - | |
| Trade payable | 19.60 | 19.60 | 19.60 | 120 | 4 |
| Other financial liabilities | 7.49 | 7.49 | 7.49 | 190 | 9 |

iv. Market risk

Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company's income or the value of its holdings of financial instruments. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables. The Company is exposed to market risk primarily related to foreign exchange rate risk. Thus, our exposure to market risk is a function of revenue generating and operating activities in foreign currency. The objective of market risk management is to avoid excessive exposure in our foreign currency revenues and costs.

v. Interest rate risk

Interest rate risk can be either fair value interest rate risk or cash flow interest rate risk. Fair value interest rate risk is the risk of changes in fair values of fixed interest bearing investments because of fluctuations in the interest rates. Cash flow interest rate risk is the risk that the future cash flows of floating interest bearing investments will fluctuate because of fluctuations in the interest rates.

Exposure to interest rate risk

Company's interest rate risk arises from borrowings. Borrowings issued at fixed rates exposes to fair value interest rate risk. The interest rate profile of the Company's interest-bearing financial instruments as reported to the management of the Company is as follows.

| | 31 March 2025 | 31 March 2024 |
|--|---------------|---------------|
| Fixed-rate instruments | | |
| Financial liabilities - measured at amortised cost | | |
| Vehicle Loan | 4.41 | 4.31 |
| Total | 4.41 | 4.31 |

Fair value sensitivity analysis for fixed-rate instruments

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss.

Therefore, a change in interest rates at the reporting date would not affect profit or loss.

Notes to the Financial Statements for the year ended 31 March 2025

33. Capital Management

For the purpose of the Company's capital management, capital includes issued capital and other equity reserves. The primary objective of the Company's Capital Management is to maximise shareholders value. The Company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants.

As at 31 March 2025, the Company has only one class of equity shares and has no long term debt. Consequent to such capital structure, there are no externally imposed capital requirements. The Company allocates its capital for distribution as dividend or re-investment into business based on its long term financial plans.

34 Ratios

(Rs in Millions)

| Particulars | Numerator | Denominator | As at | As at | Variance | |
|--------------------------------------|------------------------------------|--|-----------|-----------|----------|--|
| | | 74 | 31-Mar-25 | 31-Mar-24 | variance | |
| (a) Current Ratio | Current Assets | Current Liabilities | 6.33 | 5.42 | 16.9% | |
| (b) Debt-Equity Ratio | Total Liabilities | Shareholder's Equity | 0.01 | 0.02 | -30.2% | |
| (c) Debt Service Coverage Ratio | Net Operating income | Debt service = Interest + Principal repayments | 12.11 | 9.10 | 33.1% | |
| (d) Return on Equity Ratio | Net Profit After Taxes | Average Shareholder's Equity | 16% | 18% | -13.1% | |
| (e) Inventory turnover ratio | Cost of goods sold | Average Inventory | 56.53 | 58.82 | -3.9% | |
| (f) Trade Receivables turnover ratio | Revenue | Average Trade Reveivables | 4 | 3 | 19.0% | |
| (g) Trade payables turnover ratio | Purchases | Average Trade Payables | 20 | 17 | 16.9% | |
| (h) Net capital turnover ratio | Revenue | Working Capital | 2 | 2 | 9.9% | |
| (i) Net profit ratio | Net Profit After Taxes | Revenue | 8% | 9% | -15.6% | |
| (i) Return on Capital employed | Earnings before interest and taxes | Capital Employed | 22% | 23% | -5.4% | |
| (k) Return on investment | Income generated from investments | Average Investments | 7.48% | 8.54% | -12.4% | |

Note (b) - Debt-Equity Ratio - Decreased due to part payment of borrowings i.e term loan taken for the purchase of car Mercedes Benz

Note (c) - Debt Service Coverage Ratio - Decrease due to principal repayments and interest on borrowings in the FY25 and also decrease in net operating income as compared to the previous year.



Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Notes to the Financial Statements for the year ended 31 March 2025

35 Related Party Disclosures, as required by Indian Accounting Standard 24 (Ind AS 24) are given below:

A Relationships:

I Holding Company

Advanced Enzyme Technologies Limited

II Fellow Subsidiaries

Advanced Enzytech Solutions Limited

JC Biotech Private Limited

Scitech Specialities Private Limited

Saiganesh Enzytech Solutions Private Limited

Advanced Enzymes USA, Inc.

Advanced Enzymes Europe B.V.

Advanced Enzymes (Malaysia) Sdn. Bhd. (up to 08 November 2023)

Cal India Food International, USA (subsidiary of Advanced Enzymes USA, Inc.)

Advanced Supplementary Technologies Corporation, USA (Wholly owned subsidiary of Advanced Enzymes USA, Inc.)

Enzyme Innovation Inc., USA (Wholly owned subsidiary of Cal India Foods International)

Starya Labs Inc (Wholly owned subsidiary of Advanced Enzymes USA, Inc. from 09 December 2024)

Evoxx Technologies GMBH, Germany (Wholly owned subsidiary of Advanced Enzymes Europe B. V.)

III Key Management Personnel

Managing Director:

Mr. Omprakash B. Singh

B. Nature of transactions:

The following transactions were carried out with the related parties mentioned in A above, in the ordinary course of business.

| The following transactions were earlied out with the real | nea paraes mentronea m 11 m | ore, in the orentary o | Julie of Buenem | Rs in Millions |
|---|--|---|---|---|
| | Holding Co | ompany | KM | P |
| | 31 March 2025 | 31 March 2024 | 31 March 2025 | 31 March 2024 |
| Purchases of Goods | | | | |
| Advanced Enzyme Technologies Ltd | 305.44 | 281.10 | - | (4) |
| | Other Relat | ed Party | | |
| | 31 March 2025 | 31 March 2024 | | |
| Remuneration to Directors & their Relatives | • | | | |
| Mr. Omprakash B. Singh | * | 2.1 | 10.32 | 9.38 |
| | 31 March 2025 | 31 March 2024 | | |
| Accounts Payable | | | | |
| Advanced Enzyme Technologies Ltd | 10.30 | 19.60 | 2 | 2 |
| Dividend Paid | 31 March 2025 | 31 March 2024 | | |
| Advanced Enzyme Technologies Ltd | 24.00 | 12.00 | * | - |
| Mr. Omprakash B. Singh | = | | 16.00 | 8.00 |
| | Purchases of Goods Advanced Enzyme Technologies Ltd Remuneration to Directors & their Relatives Mr. Omprakash B. Singh Accounts Payable Advanced Enzyme Technologies Ltd Dividend Paid Advanced Enzyme Technologies Ltd | Purchases of Goods Advanced Enzyme Technologies Ltd Other Relations 31 March 2025 Remuneration to Directors & their Relatives Mr. Omprakash B. Singh 31 March 2025 Accounts Payable Advanced Enzyme Technologies Ltd Dividend Paid Advanced Enzyme Technologies Ltd 24.00 | Holding Company 31 March 2025 31 March 2024 | 31 March 2025 31 March 2024 31 March 2025 Purchases of Goods 305.44 281.10 - Other Related Party 31 March 2025 31 March 2024 - 10.32 Remuneration to Directors & their Relatives Mr. Omprakash B. Singh - - 10.32 Accounts Payable Advanced Enzyme Technologies Ltd 10.30 19.60 - Dividend Paid Advanced Enzyme Technologies Ltd 31 March 2025 31 March 2024 - Advanced Enzyme Technologies Ltd 24.00 12.00 - |

6 Managing Director of the Copmany has given personal guarantee in respect of Cash Credit facility taken from Citi Bank.

Terms and conditions of transactions with related parties; The transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. For the year ended 31 March 2025, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (31 March 2024: Rs. Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.



Advanced Bio-Agro Tech Limited

CIN: U24100MH2004PLC149464

Notes to the Financial Statements for the year ended 31 March 2025

As required by section 135 of Companies Act, 2013 and Rules therein, a Corporate social responsibility committee has been formed by 36 the Company. The Company has spent the following amount during the year towards corporate social responsibility (CSR) for activities listed under schedule VII of the Companies Act, 2013.

| | 2024-25 | 2023-24 | | |
|---|---|----------------|--------------------------------|--|
| Gross amount required to be spent by the Company | 1.53 | 1.56 | | |
| Amount spent by the Company during the year on purpose other than construction/ | | | | |
| acquisition of assets* | 1.53 | 1.56 | | |
| Shortfall at the end of the year | | * | | |
| Total of previous year short fall | - | | | |
| Reason for shortfall | Not applicable | Not applicable | | |
| Nature of CSR Activities | Various activities like people below the poverty | | | |
| | line & upliftment of Eco-Socio backward society by providing Health, Education and (Skill Development) Self-Employment, Blood | | | |
| | | | Donation, Eyes Donation, Women | |

*The Committee of Corporate Social Responsibility (CSR) had approved the budget of Rs 1.53 million (31 March 2024: 1.56 million), the Company contributes to the various projects undertaken by various organisations. During the year the amount spent is Rs 1.53 million (31 March 2024: Rs 0.15 million) on the ongoing projects. The Company has spent the full amount of Rs 1.53 million as on 31st March 2025 (31 March 2024: Amount Rs 1.45 million was transfered to in seperate bank account-unspent CSR account).

37 Other Statutory Information

- The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- The Company does not have any transactions with companies struck off.
- The Company has complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.
- The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period. (iv)
- The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year. The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities
- (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities
- (vi) identified in any manner whatsoever by or on behalf of the company Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed (viii) as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

| 38 Contingent Liabilities not provided for: | 2024-25 | 2023-24 |
|---|---------|---------|
| TDS Demands | 0.02 | 0.08 |
| Income Tax | 3.24 | 8.7 |

39 The figures for the corresponding previous year have been regrouped and/or rearranged wherever considered necessary.

For M M Nissim & Co LLP

Chartered Accountants

Firm Registration no. 107122W/W100672

Dimple Maru

Partner M. No.: 141312 Place: Mumbai

Date: 26th April, 2025 UDIN - 25141312BMJKDJ2599 For and on behalf of Board of Directors of Advanced Bio-Agro Tech Limited

Managing Director

DIN: 00015162

Place: Pune Date: 26/04/2025 Mukund M. Kabra Director DIN: 00148294

Place: Nashik

Date: 26/04/2025

Beni P. Rauka Director DIN: 00295213 Place: Thane Date: 26/04/2025